Plain-English translation of NCT07241390 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This study is testing a medication called to see if it can reduce serious heart-related events in people who have heart disease and/or chronic kidney disease. About 7,140 people will participate over roughly 5 years. Half will receive the new medication along with their regular care, and half will receive a placebo (inactive pill) along with their regular care.
People with heart disease or chronic kidney disease are at high risk for serious heart events. Doctors want to know if this medication can help prevent these events and improve outcomes beyond current standard treatments.
You likely qualify if…
You likely don't qualify if…
You will take a daily oral medication (or placebo) along with your regular medical care for about 5 years. You'll have regular study visits to check how the medication is working and monitor your heart and kidney health. The study team will track whether you experience any serious heart events during this time.
AI-generated summary from trial data · Jul 16, 2026 · Not medical advice
Argentina